MX2022015495A - Inhibidores de cinasa relacionada con el gen a nunca en mitosis (nek7). - Google Patents

Inhibidores de cinasa relacionada con el gen a nunca en mitosis (nek7).

Info

Publication number
MX2022015495A
MX2022015495A MX2022015495A MX2022015495A MX2022015495A MX 2022015495 A MX2022015495 A MX 2022015495A MX 2022015495 A MX2022015495 A MX 2022015495A MX 2022015495 A MX2022015495 A MX 2022015495A MX 2022015495 A MX2022015495 A MX 2022015495A
Authority
MX
Mexico
Prior art keywords
sup
nek7
inhibitors
compounds
kinase
Prior art date
Application number
MX2022015495A
Other languages
English (en)
Inventor
David James Bearss
Alexis Henri Abel Mollard
Iii John Sai Keong Kauwe
Original Assignee
Halia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Halia Therapeutics Inc filed Critical Halia Therapeutics Inc
Publication of MX2022015495A publication Critical patent/MX2022015495A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Se proporcionan compuestos que tienen actividad como inhibidores de NEK7. Los compuestos tienen la Estructura (I): (ver Fórmula) (I) o una sal, estereoisómero o profármaco farmacéuticamente aceptable de los mismos, en donde A, X, Y, R1, R2, R3 y R4 son como se definen aquí. También se proporcionan métodos asociados con la preparación y el uso de los compuestos, composiciones farmacéuticas que comprenden los compuestos y métodos para modular la actividad del inflamasoma NLRP3.
MX2022015495A 2020-06-08 2021-06-08 Inhibidores de cinasa relacionada con el gen a nunca en mitosis (nek7). MX2022015495A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063036244P 2020-06-08 2020-06-08
US202163170776P 2021-04-05 2021-04-05
US202163185257P 2021-05-06 2021-05-06
PCT/US2021/036398 WO2021252488A1 (en) 2020-06-08 2021-06-08 Inhibitors of nek7 kinase

Publications (1)

Publication Number Publication Date
MX2022015495A true MX2022015495A (es) 2023-03-14

Family

ID=76731040

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015495A MX2022015495A (es) 2020-06-08 2021-06-08 Inhibidores de cinasa relacionada con el gen a nunca en mitosis (nek7).

Country Status (13)

Country Link
US (1) US20230203045A1 (es)
EP (1) EP4161933A1 (es)
JP (1) JP2023528659A (es)
KR (1) KR20230035311A (es)
CN (1) CN116075513A (es)
AU (1) AU2021289345A1 (es)
BR (1) BR112022025012A2 (es)
CA (1) CA3186041A1 (es)
CO (1) CO2022019131A2 (es)
IL (1) IL298849A (es)
MX (1) MX2022015495A (es)
TW (1) TW202208368A (es)
WO (1) WO2021252488A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159835A1 (en) * 2021-01-25 2022-07-28 Halia Therapeutics, Inc. Nek7 inhibitors
WO2024059200A1 (en) * 2022-09-14 2024-03-21 Halia Therapeutics, Inc. Nek7 inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US20110189167A1 (en) 2007-04-20 2011-08-04 Flynn Daniel L Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
WO2013104561A1 (en) 2012-01-12 2013-07-18 Basf Se Herbicidal isoxazolo[5,4-b]pyridines
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
MX2018004359A (es) 2015-10-09 2018-05-01 Abbvie Sarl Pirazolo [3,4-b] piridin-6-carboxamidas n-sulfoniladas y metodo de uso.
CN108250200A (zh) 2016-12-28 2018-07-06 中国科学院上海药物研究所 一种具有Axl抑制活性的化合物及其制备和应用
DE102017200543A1 (de) 2017-01-13 2018-07-19 Baden-Württemberg Stiftung Ggmbh Verfahren zur Behandlung einer Oberfläche eines Hartmetallkörpers und zur Beschichtung des behandelten Hartmetallkörpers mit einer Diamantschicht
MA49903A (fr) * 2017-08-15 2020-06-24 Inflazome Ltd Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
KR20200087759A (ko) 2017-11-09 2020-07-21 인플라좀 리미티드 신규한 설폰아마이드 카복스아마이드 화합물
AU2019249721A1 (en) * 2018-04-05 2020-09-17 Merck Patent Gmbh Heteroaryl compounds as type II IRAK inhibitors and uses hereof
AR118119A1 (es) 2019-02-18 2021-09-22 Genentech Inc Compuestos de pirido-pirimidinilo y métodos de uso
CN111646995B (zh) * 2019-03-04 2023-03-21 四川大学 4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途
KR20220062366A (ko) * 2019-09-26 2022-05-16 센젠 타겟알엑스, 아이엔씨. 치환된 방향족 융합 고리 유도체, 및 이를 포함하는 조성물, 및 이의 용도

Also Published As

Publication number Publication date
IL298849A (en) 2023-02-01
CA3186041A1 (en) 2021-12-16
US20230203045A1 (en) 2023-06-29
BR112022025012A2 (pt) 2023-02-14
EP4161933A1 (en) 2023-04-12
KR20230035311A (ko) 2023-03-13
CN116075513A (zh) 2023-05-05
TW202208368A (zh) 2022-03-01
WO2021252488A1 (en) 2021-12-16
JP2023528659A (ja) 2023-07-05
CO2022019131A2 (es) 2023-03-07
AU2021289345A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2021005924A (es) Compuestos y metodos de uso de los mismos para el tratamiento del cancer.
MX2022013984A (es) Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7).
MX2019013954A (es) Inhibidores covalentes de kras.
JOP20220155A1 (ar) مشتقات البيرازول مفيدة كعوامل مضادة للسرطان
PH12019502245A1 (en) Compounds that inhibit mcl-1 protein
MX2020013817A (es) Compuestos de naftiridinona sustituidos utiles como activadores de celulas t.
MX2020013373A (es) Compuestos de naftiridinona utiles como activadores de celulas t.
WO2016164675A8 (en) Substituted quinazoline compounds and methods of use thereof
CR20230310A (es) Inhibidores de prmt5
WO2021055728A8 (en) Small molecule inhibitors of kras g12c mutant
MX2009013832A (es) Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
MX2022015495A (es) Inhibidores de cinasa relacionada con el gen a nunca en mitosis (nek7).
MX2022007130A (es) Derivados de piperazina sustituidos utiles como activadores de celulas t.
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
AU2019375825A8 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
ZA202206481B (en) Amide derivative and preparation method therefore and use thereof in medicine
CR20220538A (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
MX2020013729A (es) Compuestos de cianotriazol y usos de los mismos.
CO2023014204A2 (es) Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7)
MX2022004213A (es) Derivados de 2-azaspiro[3.4]octano como agonistas de m4.
MX2022004215A (es) Derivados de 2-azaespiro[3.4]octano como agonistas de m4.
MX2022006104A (es) Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma.
MX2022003617A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer.